Safety and Efficacy of Ellacor® Micro-coring® Following Best Practices on Technique and Post-Procedural Care
Condition(s) studied
Investigational drug(s) / intervention(s)
ellacor Micro-Coring Technology: ellacor will be used to treat moderate-severe wrinkles in the mid to lower face in subjects aged between 45-65.
Study summary
Since its inception of being marketed in the United States in 2021, physicians have used various post procedure skin care regimen to facilitate recovery. This study aims to examine the use of three post care products in five skin care regimens
Eligibility
Primary outcome measure(s)
- Global Aesthetic Improvement Scale (GAIS) — GAIS Assessment will be performed under a timeframe of 90 days
Treatment improvement will be evaluated based off the 7 grade GAIS by both the subject and the physician.
Trial sites (2)
| Facility | City | Region | Status |
|---|---|---|---|
| Miami Dermatology And Laser Institute | Miami | Florida | |
| Caloaesthetics Plastic Surgery Center | Louisville | Kentucky |
More Cytrellis Biosystems, Inc. trials in the USA
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT07260578 on ClinicalTrials.gov ↗ ← All trials in the USA